Whalesbook
Systematix Group ke pharma analyst Vishal Manchanda keh rahe hain ki ye saaf nahi hai ki US government ye tariffs lagayegi bhi ya nahi. Lekin agar lagti bhi hain, toh pharma companies, especially Indian generics waali, zyada chinta na karein.
Unka kehna hai ki ye policies basically branded aur patented drugs par focus karengi, na ki un generic medicines par jo US healthcare system ke liye bahut important hain. Agar tariffs aate bhi hain, toh sirf un companies ko thoda effect hoga jinki branded drugs mein kaafi holding hai. Sun Pharma, jo US mein specialty drugs mein kaafi active hai, unko shayad pricing agreements karne pad sakte hain, bilkul waise hi jaise baaki global companies karti hain.
Manchanda kehti hain ki generic drugs par tariffs lagna lagbhag na mumkin hai, kyunki ye medicines US ki healthcare supply chain ka ek essential hissa hain. Jinhone pehle se hi US ke saath agreements kiye hain, woh risk se bach gaye hain.
Sun Pharma ke liye analyst ka outlook kaafi positive hai. Company ne US generics par apna reliance kam kiya hai aur branded products ka share badhaya hai. Agar sabse bura scenario bhi dekha jaaye, toh bhi companies par financial impact sirf 2-3% EBITDA tak hi seemit rahega. Ye ek controlled downfall hai, badi giraawat nahi.